|1.||Yamashita, Makoto: 6 articles (10/2013 - 01/2009)|
|2.||Kubo, Shuku: 5 articles (10/2013 - 01/2009)|
|3.||Kakuta, Masayo: 4 articles (10/2013 - 01/2009)|
|4.||Tomozawa, Takanori: 3 articles (10/2013 - 01/2009)|
|5.||Yoshiba, Satoshi: 2 articles (02/2011 - 11/2010)|
|6.||Ishizuka, Hitoshi: 2 articles (02/2011 - 11/2010)|
|7.||Yoshihara, Kazutaka: 2 articles (02/2011 - 11/2010)|
|8.||Okabe, Hiromi: 2 articles (02/2011 - 11/2010)|
|9.||Tokumitsu, Akane: 2 articles (03/2010 - 01/2009)|
|10.||Zhong, Jiankang: 1 article (12/2014)|
01/01/2010 - "Prophylactic single administration of CS-8958, as early as 7 days prior to infection, also showed superior efficacy. "
03/01/2010 - "In this study, CS-8958 was administered just once 7 days before infection and showed significant efficacy in vivo. "
02/01/2010 - "A single dose of CS-8958 given seven days prior to virus infection also protected mice against H5N1 virus lethal infection. "
01/01/2009 - "A prolonged survival effect was observed after a single administration of CS-8958, even if it was given 7 days before infection. "
10/01/2010 - "Furthermore, a single intranasal administration of CS-8958 showed a superior reduction of virus load in lungs in mouse infection model. "
|2.||Human Influenza (Influenza)
11/01/2010 - "CS-8958, when inhaled by healthy volunteers, is well tolerated and exhibits a suitable pharmacokinetic profile, suggesting potential for long-lasting anti-influenza activity."
03/01/2010 - "These results suggest that since CS-8958 is characteristically long lasting in the lungs, it may be ideal for the prophylaxis and treatment of influenza."
02/01/2010 - "CS-8958 functions as a long-acting NA inhibitor in vivo (mice) and is efficacious against seasonal influenza strains following a single intranasal dose. "
01/01/2010 - "Finally, the potential of a single inhalation of CS-8958 for influenza patients was demonstrated by clinical studies, and CS-8958 has been approved and is commercially available as Inavir(®) (Daiichi Sankyo Co., Ltd, Tokyo) in Japan."
03/01/2010 - "CS-8958, a prodrug of laninamivir (R-125489), is currently under development as an inhaled anti-influenza drug. "
|3.||Body Weight (Weight, Body)
11/01/2009 - "In this study, the tissue distribution profiles after a single intranasal administration of CS-8958 (0.5 micromol/kg of body weight) to mice were investigated, focusing especially on the retention of CS-8958 in the respiratory tract by comparing it with R-125489 and a marketed drug, zanamivir. "
|4.||Renal Insufficiency (Renal Failure)
02/01/2011 - "The area under the concentration-time curve extrapolated to infinity (AUC(0-inf)), maximum concentration (C(max)), and time to C(max) of CS-8958 did not change with the degree of renal impairment, whereas the half-life (t(1/2)) of CS-8958 increased with increasing renal insufficiency. "
02/01/2011 - "CS-8958 was well tolerated by all the subjects, although increasing renal dysfunction leads to increasing systemic exposure to laninamivir, particularly in severe renal insufficiency."
|6.||caprylic acid (octanoate)